Source: CureToday articles
Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma.
Recent Content
- KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety
- Rilonacept in Recurrent Pericarditis: Mechanism of Action, Patient Management, and Clinical Considerations
- Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation
- Op-Ed: Expand Patient Choice to Lower Medication Costs
- Sasanlimab-BCG Combo May Delay Recurrence in Bladder Cancer
- Meta-Analysis Evaluates RSV Viral Load and Symptom Kinetics
- Personalized Vaccine Elicits Responses in Patients With Kidney Cancer
- SCIg More Effective Immunoglobulin Option for Immunocompromised Patients With Inborn Errors of Immunity
- GLP-1 Receptor Agonists Demonstrate Increased Risk of Neovascular Age-Related Macular Degeneration in Diabetes
- The Invisibility of Blood Cancers to Others